[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 249
Citations 0
Comment & Response
May 2014

The Future of Neuroscience Clinical Trials

Author Affiliations
  • 1National Institute of Neurological Disorders and Stroke, National Institutes of Health
  • 2National Cancer Institute, National Institutes of Health
JAMA Neurol. 2014;71(5):652. doi:10.1001/jamaneurol.2014.165

To the Editor We appreciate Love and Fathallah-Shaykh1 bringing the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) to the attention of the JAMA Neurology readership, and we would like to address the questions raised around NeuroNEXT plans for intellectual property, data sharing, industry involvement, indemnification, and funds for study oversight. In NeuroNEXT, applicants who use the U01 and U44 mechanisms will maintain intellectual property protections afforded under the Bayh-Dole Act (35 USC 201 and 37 CFR 401) so that ownership of intellectual property remains with the inventing site’s institution.